

▲Measure #105: Three-dimensional Radiotherapy for Patients with Prostate Cancer

**DESCRIPTION:**

Percentage of patients, regardless of age, with prostate cancer receiving external beam radiotherapy to the prostate *only* (no metastases) who receive 3D-CRT or IMRT

**INSTRUCTIONS:**

This measure is to be reported each time an external beam radiotherapy to the prostate procedure is performed during the reporting period for prostate cancer patients. It is anticipated that clinicians who perform external beam radiotherapy to the prostate will submit this measure.

**This measure is reported using CPT Category II codes:**

ICD-9 diagnosis codes and CPT procedure codes are used to identify patients who are included in the measure's denominator. CPT Category II codes are used to report the numerator of the measure.

When reporting the measure, submit the appropriate ICD-9 diagnosis codes, CPT procedure codes, and the appropriate CPT Category II code(s) **OR** the CPT Category II code(s) **with** the modifier. The modifier allowed for this measure is: 8P- reasons not otherwise specified. There are no allowable performance exclusions for this measure.

**NUMERATOR:**

Patients who receive three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT)

***NUMERATOR NOTE:** The correct combination of numerator code(s) must be reported on the claim form in order to properly report this measure. The "correct combination" of codes may require the submission of multiple numerator codes.*

**Numerator Coding:**

**3D-CRT or IMRT Received**

*(Two CPT II codes [4165F & 4200F] are required on the claim form to submit this category)*

**CPT II 4165F:** Three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT) received

**AND**

**CPT II 4200F:** External beam radiotherapy to prostate only

**OR**

**If patient is not eligible for this measure because the 3D-CRT or IMRT is to region(s) other than the prostate only, report:**

*(One CPT II code [4201F] is required on the claim form to submit this category)*

**CPT II 4201F:** External beam radiotherapy for prostate cancer to region(s) other than prostate only

**OR**

**3D-CRT or IMRT not Received, Reason not Specified**

*(Two CPT II codes [4165F-8P & 4200F] are required on the claim form to submit this category)*

Append a reporting modifier (**8P**) to CPT Category II code **4165F** to report circumstances when the action described in the numerator is not performed and the reason is not otherwise specified.

- **4165F with 8P:** Patients who did not receive three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT), reason not otherwise specified

**AND**

**CPT II 4200F:** External beam radiotherapy to prostate only

**DENOMINATOR:**

All patients, regardless of age, with prostate cancer receiving external beam radiotherapy to the prostate *only* (no metastases)

**Denominator Coding:**

An ICD-9 diagnosis code for clinically localized prostate cancer without a secondary malignant neoplasm diagnosis of a specified site (respiratory, digestive, and of other specified sites) and a CPT procedure code for patients receiving external beam radiotherapy to the prostate are required to identify patients for denominator inclusion.

**ICD-9 diagnosis code:** 185

**WITHOUT**

**ICD-9 diagnosis codes:** 197.0, 197.1, 197.2, 197.3, 197.4, 197.5, 197.6, 197.7, 197.8, 198.0, 198.1, 198.2, 198.3, 198.4, 198.5, 198.6, 198.7, 198.81, 198.82, 198.89

**AND**

**CPT procedure codes:** 77401, 77402, 77403, 77404, 77406, 77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 77418, 77427

**RATIONALE:**

Current, computer-aided radiotherapy techniques improve the precision of the irradiation of cancerous tissue and should be employed for all patients receiving external beam radiotherapy to the prostate.

**CLINICAL RECOMMENDATION STATEMENTS:**

Three-dimensional CRT or intensity-modulated radiation therapy (IMRT) techniques should be employed over conventional techniques. These techniques use computer software to integrate CT images of the patients' internal anatomy in the treatment position, which allows the volume receiving the high radiation dose to "conform" more exactly to the shape of the tumor. Three-dimensional CRT has reduced both acute and late normal tissue toxicity in patients with prostate cancer and allows higher cumulative doses to be delivered with a lower risk of late effects. (NCCN) (Category 2A)